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C;.};(:;;gyi Medica/ Unil"ersi4y, Ddn? t~;' J(), H-6 72(), Szc'.~'ed, Hungaly 
Ab stract. J.~,'1 c'vc'n 4-ph c'ny!-_)', _~-d ia cet.yl - J, 4-d ihy'd ropy"'id m c's 
substltllted at the phenyl ljl7g T4'el~' (ACDHP~) /GI-11/ ･' ,' 
syn.th.c'si~-ec! cmcl compcu'ed J'or their c:ytot:oxic activit.y and 
ml.dticl/'u.~J /~!'sis!cu'zce (j~4:DR)-J'e)'ersil?(g actit!ity. in in. ~'itlv assay 
,systc',7'Is. An'lon.~! them,, col?7pound IG7/ showc'd t/?e hi.~'/?est 
cytotoxic ctctivi!y agai,'Ist hu,mcu't promyelocytic !eukemia HL-60 
a/?ct 17ul7lan sclua/7?ot.!s celi carcinol7la HSC-_2 cells. Howel'e/1 no 
col7lpounc/s testecl plvducc'cl /rldica/s al pH 7.4- J_~.5. The actil"ity 
of P-.{>'!.ycopl'otein (P.~Jp) ;~'s'ponsible .f~)r MDR il? tum.or cel[s was 
rechlced b.y col77pouncis fG2, 3, 6, 5, 8. I; 11J, T,e,rlpcu77!1 fVPl 
and nj/~c.lipil?e /NP/･ Hovvel'ei, compounc!s IG4, 7, 101 wc'/~;' 
h.ardly' actil'e while G9 ctk.t not sl?ovv a MDR reversin.~(' c'_ff~ct at 
2. 0-2(). O ,t.t.~'/ml*. T/?ese ciatc7 sl?on! a fl~'latiol'Iship bc't}4'een 
che/7lic:a/ stnlctul'es and MDR-;~i't.'ersing c(1lt･ct oJ1 tz.imoJ' cc'!/s. 
The cievelopment of multidrug resist',mce (MDR)-tumor cell 
populations is 'a m'ajor prol.~lem in the chemotherapy of 
humtm c'ancer (1~. When tumor cells become resist'ant to 
antic'.tncer 'agents such 'as vi/'1ca 2tlkaloicis or anthracyc]ines, 
they often show resistance to other 'antitumor agents wrth 
different structures and mechanisms of action. One of the 
MDR types w'as provec] to in¥rolve 'a membrane-bound 
protein, P-glycoprotein (P~~p) in MDR cancer cells, protozoa 
and bacteria. This protein acts 'as an efilux pump for 
'anticancer drugs (2). Recently, various compounds have been 
showl~ to inhibit Pgp-mediatecl clrug efflux (3). These 
compouncis inclucle ion channel blockers SLlch '.Is verapamil 
(VP) (4), clihyclropyridincs (DHPs) (5), propafenone (6), 
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cytotoxic activity. ESR. 
antips chotic drugs like phenothiazines (7), cyclosporins (8), 
thiazinopiperidine S9788 (9), acriclone carboxamlde 
GF120C)~ IS (1()), quinoline MS209 (ll), and stipiamide (12). 
Among them, DHPs, calcium antagonists, have been studied 
extensively for the analogy to VP (5). In a combination 
treatment wi h antitumor 'agents, such as vinca alkaloids or 
a thr cyclines, c'alcium anta~~cronist VP caused cardiovascular 
sicie effects (4). It is vel~y import,ant fincling th',rt DHPs, which 
do not have any c',ii~ ,ium 'antagonistic actlvity, possess MDR 
reversal activity (5). From the structure-activity relationship 
on DHP calc',ium channel antagonists, the role of C-3 and C-5 
substituents  the DHP ring has received attention (~13 ). 
Genei'a ly, the antagonist activity is optimized by ester 
substituents 'at 3- "and 5-positions ancl is reduced by their 
replacement with an 'acetyl group (13). In this p'aper, we 
investigate the cy ot xi  and the MDR-reversal activities of 
3,5-diace yl-2,6-dimethyl-1 ,4-clih.vclropyricline (ACDHP) cleri-
vatives 'against mouse lymphoma cells tr'ansfected with M.DR 
1 gene. 
Materia.Is and Methods 
The meltin~ points of AcDI-lPs we~~c cieten~lincc{ in open glass capii]aries 
in ~i ptirziffin bath anci t~re unco~'i'ected. H-NMR spcctra werc 
perfo~~mecl ol~ "i JEOL JNM-GSX 50O (_500 Mllz) spectromcter using 
tetr~imethylsi]2~ne as an int ~'~~al standarcl. Mass spectra (MS) were 
recorc{ecl on a~ JEOL-JMS-DX300 spect~~o~~lcter with a direct inlet 
syste~n at 70eV. Co~~lbustion analyscs were carried out on Co!eman 
ele~~~ental 2i~~~ilyser at V',tdoci',ira, rncli2~. TI_C (Thi;1 Iayer 
chro~Tltitography) was perfo~'mecl on a Merck Kiesclgcl ()O F'~254 (Merck 
~.5_~~49. USr¥). 
Chenli a!s. ACDHPS ¥vere ne¥viy synthesized (i4) 'ancl the structures are 
shown i~~ Figure l. The follo¥ving chemicals were obtained from e'ach 
i~~diczrted company: VP (Alc]rich); NP (Wako Pure Chem. Ltd., Osaka); 
RPM11()40 ~~lediu~rl (GIBCo, Gr2md Isl',md, NY, USA); ~lscorbic ~lcid 
(Tokv.o Kzisei Kogyo. Co. Ltd., Japa~~); fcta} bovine serum (FBS) (JRH 
Biosci., Lenexa, KS, USA). 
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Geneilal procedure for the preparation ofACDHPS fG1-11J. A solution of 
acety]acetone (1.0 g, 10 mmol) and liquor ammonia (sp. gr. 0.90) (0.32 
mL, ~_O mmol) in MeOH (10 mL) was treated with respective aldehyde 
(5 mmol), and the mixture was refluxed for 20-24 hours. The separated 
solid was collected by suction. The reaction mass was kept for 24-36 
hours and then, after charcoal treatment, recrystallized from MeOH. 
The following compounds were obtained: 
a) 3,5-Diacetyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine [G1]. 
mp: 204-206'C (MeOH) (Lit. 15: mp 211-212'C). yield: 42%. 
b) 3,5-Diacetyl-1,4-dihydr0-2,6-dimethyl-4-(3-phenoxyphenyl)pyridine 
[G2]. mp: 175-176'C (MeOH). yield: 37%. IH NMR (CDC13) ~: 2.25 
(s, 6H), 2.28 (s, 6H), 5.06 (s, IH), 5.82-5.92 (br, IH), 6.73 (dd, IH, 
J=2.4, 8.2 Hz), 6.86+6.87 (d, IH, J=2.1 Hz), 6.94 (d, 2H, J=7.9 Hz), 
6.97 (d, IH, J=7.6 Hz), 7.06 (t, IH, J=7.3 ,z), 7.15 (t, IH, J=7.9 Hz), 
7.28 (t, 2H, J=7.9 Hz) MS m/e: 361 (M , 26%) 192 (100a/o) Anal 
Calcd for C23H23N03: C, 76.45; H, 6.37; N, 3.87. Found: C, 76.52; H, 
6.42; N, 3.81. 
c) 3,5-Diacetyl-4-(3-chlorophenyl)- I ,4-dihydr0-2,6-dimethylpyridine 
[G3]. mp: 209-210'C (MeOH). yield: 470/0. IH NMR (CDC13) ~: 1.54 
(s, 6H), 1.63 (s, 6H), 4.40+(s, IH), 6.38-6.50 (m, 4H), 8.08 (s, IH). MS 
m/e: 305+303 (1:3) (M , 7010:22%), 192 (100alo). Anal Calcd for 
C17Hi8CIN02: C, 67.21; H, 5.9~; N, 4.61. Found: C, 67.26; H, 5.90; N, 
4.70. 
d) 3,5-Diacetyl-1,4-dihydr0-4-(4-hydroxy-3-methoxyphenyl)-2,6-
dimethylpyridine [G4]. mp: 195-197'C (MeOH). yield: 53"/o. IH 
NMR (CDC13) 6: 2.25 (s, 6H), 2.31 (s, 6H), 3.82 (s, 3H), 5.03 (s, IH), 
5.40-5.52 (br, IH), 5.70 (s, IH), 6.74 (dd, IH, J=2.1, 8.2 ~z), 6.74 (d, 
IH, J=8.2 Hz), 6.81 (d, IH,J=2.1 Hz). MS m/e: 315 (M , 32%), 192 
(100%). Anal Calcd for Cl8H21N04: C, 68.57; H, 6.66; N, 4.44. 
Found: C, 68.63; H, 6.60; N, 4.51. 
e) 3,5-Diacetyl-1 ,4-dihydr0-2,6-dimethyl-4-(4-dimethylaminophe-
nyl)pyridine [G51･ mp: 219-220"C (MeOH). yield: 33%. iH NMR 
(CDC]3) 6: 2.25 (s, 6H), 2.29 (s, 6H), 2.87 (s, 6H), 4.94 (s, IH), 5.82 
(s, IH), 6.60 (d, 2H, J=8.5 Hz), 7.07 (d, 2H, J=8.5 Hz). MS m/e: 314 
(M+, 2010), 311 (100%). Anal Calcd for C19H24N202: C, 73.07; H, 
7.69, N, 8 97. Found. C, 73 14, H, 7 76, N, 8 93. 
f) 3,5-Diacetyl-1 ,4-dihydr0-4-(4-methoxyphenyl)-2,6-dimethylpyridine 
[G6]. mp: 171-172'C (MeOH). yield: 58%. IH NMR (CDC13) 6: 2.24 
(s, 6H), 2.29 (s, 6H), 3.73 (s, 3H), 5.01 (s, IH), 5.80-5.86 (br, 1+H), 6.74 
(d, 2H, J=8.8 Hz), 7.13 (d, 2H, J=8.8 Hz). MS m/e: 299 (M , 4lc~~lo), 
192 (100%). Anal Calcd for C18H21N03: C, 72.24; H, 7.02; N, 4.68. 
Found･ C, 72 29; H 7 10; N, 4 73. ?
g) 3,5-Diacetyl-4-(4-chlorophenyl)- I ,4-dihydr0-2,6-dimethylpyridine 
[G7]. mp: 180-182'C (MeOH). yield: 57a/o. IH NMR (CDC13) ~: 2.26 
(s, 6H), 2.33 (s, 6H), 5.12 (s, IH), 5.87-5.96 (br, IH), 7.16-7.21 (m, 
4H). MS m/e: 305+303 (1:3) (M+, 9%:26%), 192 (100alo). Anal Calcd 
for Cl7H18CIN02: C 6721 H 5 93 N 461 Found C 6720 H 
5.87; N, 4.56. 
h) 3,5-Diacetyl- I ,4-dihydr0-2,6-dimethy]-4-[4-(methylthio)phe-
nyl]pyridine [G8]. mp: 181-182'C (MeOH). yield: 460/0. IH NMR 
(CDC13) 6: 2.24 (s, 6H), 2.30 (s, 6H), 2.41 (s, 3H), 5.05 (s, IH), 5.89 
(s, IH), 7.09 (d, 2H, J=8.5 Hz), 7.13 (d, 2H, J=8.5 Hz). MS m/e: 315 
(M+, 44%), 192 (100%). HR MS Calcd for Cl8H21N02S: 315.1293. 
Found: 31 5.1294. 
i) 3,5-Diacetyl-4-(3-bromophenyl)-1,4-dihydr0-2,6-dimethylpyridine 
[G9]. mp: 224-226'C (MeOH). yield: 51%. IH NMR (CDC13 + 
DMSO-d6) ~: 1.73 (s, 6H), 1.82 (s, 6H), 4.59 (s, IH), 6.59 (t, IH, 
J=7.8 Hz), 6.66 (d, IH, J=7.9 Hz), 6.72 (d, IH, J+~~7.6 Hz), 6.81 (s, 
IHO), 8.14 (s, IH). MS m/e: 349+38i7 (1:i) (M , 130/0:15%), 192 
(100%). HR MS Calcd for Cl7H18 BrN02): 347.0521 (349.0501). 
Found: 347.0506 (349.0482). 
j) 3,5-Diacetyl-4-(2-chlorophenyl)-1,4-dihydro-2,6-dimethylpyridine 
[GIO]. mp: 200-202'C (MeOH) (Lit. 15: mp 178'C). yield: 530/0. iH 
NMR (CDC13) ~: 2.24 (s, 6H), 2.29 (s, 6H), 5.40 (s, IH), 5.79 (s IH) 
7.06 (dt, IH, J=1.5, 7 6 Hz) 7 12 (dt IH J 1 2 7 6 Hz) 7 23 7 25 
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Figu e 1. St,'uctures ofACDHPs fG1-11J. 
(m, 2H). MS m/e: 305+303 (1:3) (M+, 2%:50/c), 192 (100%). Anal 
Calcd for Cl7Hl8CINO C 67 21 H 5 93 N 4 61 Found: C, 67.17; 
H, 5.87; N, 4.58. 
k) 3,5-Diacetyl-1,4-dihydr0-2,6-climethyl-4-(2-nitrophenyi)pyridine 
[Gll]. mp: 233-235'C (MeOH) (Lit. 15: mp 218'C). yield: 28a/o. IH 
NMR (CDC13+DMSO-d6) 6: 1.40 (s, 6H), 1.44 (s, 6H), 4.82 (s, IH), 
.47 (t, IH, J=7.6 Hz), 6.60 (d, IH, J=7.6 Hz), 6.68 (t, IH, J=7.6 Hz), 
6.80 (d, IH, J=7.6 Hz), 8.02 (s, IH). MS m/e: 314 (M+, 9010), 252 
(100alo). HR MS Calcd for Cl7Hl8N204: 31.4.1266. Found: 314.1278. 
Cell culture. Hurnan promye]ocytic ieukemia HL-60 cells were 
maintained at 37'C in RPM11640 medium supplemented with 100/0 FBS 
in a humidified 5% C02 atmosphere (14). Human squamous cell 
arcinoma SC-2 cel]s were maintained as a monolayer culture in 
DMEM supplemented with 10% FBS, and subcu]tured by trypsinization 
(16). 
Cytotoxic activi4y. HL-60 cells (1 x l06/rri^L) were incubated for 24 hours 
with various concentrations of test samples in the culture medium, and 
the viable ce]1 number was determined by trypan blue dye exc]usion (16). 
The 500;70 cytotoxic concentration (CC50) of each compound was 
determined by dose-response curve. The cytotoxic activity of each 
compound was also assayed with HSC-2 cells. In brief, near-confluent 
HSC-2 cel]s were treated for 24 hours with various concentrations of 
each compound and the relative viable celi number (absorbance at 540 
nm) was determined by the crystal vioiet method (17). 
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Assay jbi' irlc!ica/ intensty. The radical intensity of test samples was 
determinec] at 25'C exactly I min after mixing samples in O. IM Tris-HCl 
(pl"I 7.4), O.1M Tris-HC] (pH 8.0)(only for experiment with ascorbate), 
O.1M Nal'-iC03-Na2C03 (pH 9.5) or O.lM KOII (pH :12.5) with electron 
spin resonance (ESR) spectroscopy (JEOL JES REIX. X-band, 100 kHZ 
modulation freqt~ency). Instrument settings: center field, 335.6 t 5.0 
mT; micro¥vave po¥ver, 8 mW; modulation amp]itude, O.1 mT; gain, 2-lO 
x 100; time const'ant, O.1 sec; scanning time, 4 min. The r',Idical intensity 
w',~s definecl as the r",rtio of peak heights of these radicals to that of MnO 
(18). 
Cc'll anc!fudo,~'sc(;nce uptakc'. MRD1/A expressing' cell lines were selected 
by culturing the ini*ccted cells with 60 ng/mL colchicine to maintain the 
expression of the MDR phenotype. The L5178 MDR cell line and the 
L5178 Y parent cell line were grown in McCoy's. 5A medium ',vith 1001(, 
he'at-inactivated horse serum, L-glut'amine 'and antibiotics. The cells 
were adjusted to a density of 2 x 106/mL and resuspended in serum-free 
McCc.)y's 5A medium, ',Ind O.5 mL aiiquot of the cell suspension were 
distributcd into e'ach Eppendorf centrifuge tube. Then, 2 uL of 2 nlg/mL 
tested courpounds were added and incubated for 10 min at room 
temperature. Then, 50 l,iL rhodamine i23 (R123) ･as an indicator was 
added to the s'arnples (5.2 t,tM final conccnti'ation) and the cells ¥vere 
incub'ated for a further 20 min at 37 'C, washed t¥vice ',md resuspended in 
O.5 mL phosphate-buffered saline (PBS) for ana]ysis. The fluorescence 
of cell popuiation was measurec] by flow cytometry using Beckton 
Dickinson FACScan instrument (cell sorter). VP was used as the positive 
control in the R123 accumulation experiments (17, 18). R123 
accumulation was calculated from the fluorescence of one height value 
Xl'56 using the 2nd equation y=:lO - , In the case of logarithmic 
transformation~' the 10~_4 digital channels were s¥vitched to one decade at 
each '_56 (=2 ) channe]s. Then, the percentage of mean fluorescence 
intensity ¥v',~s calcul',rted in parental ancl MDR cell lines, compared to 
tmtreatecl cells. The fluorescence activity ratio was calcul',rted by the 
fo]lowing equation (1. 8, 19): 
Ratio = ( MDR treated/MDR control)/(parental treated/parent2~l control) 
Calculafi0,~ of distribution coeJ_r~lcient. The log P values were calculated by 
CLOGP (20). 
Results 
Cytotoxicty. Eleven ACDHPS [G1-11], VP and NP were at first 
testecl for their cytotoxicity against HL-60 and HSC-2 cell 
lines. The cytotoxic activity of G7 against HL-60 (CC50=20 
uM) and HSC-2 (CC50=41 ~tM) was the greatest among 11 
AcDHPs, and was comparable with that of VP and NP (Table 
I). Compounds [G8] and [GIO] showed moderate cytotoxicity 
in l!itro. On the other hand, the cytotoxic activity of nine 
ACDHPS Were much less. ESR spectroscopy showed that 
these compounds did not produce radicals at pH 7.4-12.5 and 
also, neither enhanced the radical intensity of sodium 
ascorbate (Table I). Therefore, it seelns likely that the 
incluction of cytotoxic activity by G7 does not relate to their 
radicals or prooxidant actions. 
MDR reve,Isal on tz,unor celJs. The Rhodamine 123 assay has 
been widely documented as a direct and reproducible assay 
for measuring Pgp-dependent efflux (21). The substituent 
effect at the benzene ring of ACDHPS Was examined. Table I 
summarizes the adtivity of compounds with different aromatic 
substituents at the 4-position. Their activity depended on the 
C-4 aryl gr up ubstitution. In the present series of 
compounds, the most lipophilic compound G2 with 3-phenoxy 
group on the phenyl ring gave the highest activity. Among 
three ortho [GIO]-, meta [G3]- and para [G7]-chloro 
derivativ s, meta-chloro compound [G3] had the highest 
activity. However, meta-bromo substituent [G9] was inactive. 
Two oltho [G1l]- and meta [Gl]-nitro compounds had almost 
similar activity. Strong electron-donating groups such as 
methoxy [G6], dimethylamino [G5] and methylthio [G8] in 
the para posit on generally gave high activity. However, no 
relation betw en MDR-modulating activity and structural 
feature could be observed from these studies. 
Lipoph.ilicity. Lipophilicity is an important parameter affecting 
MDR-modulating eff ciency on the structure-activity 
relationship of MDR dru s (22). Their log P values were 
calculated by CLOGP (Table I) (20). Among 11 AcDHPs, 3-
phenoxy derivative [G2] with the highest lipophilicity had the 
highest activity. On the other hand, the activities of more 
hydrophobic 2-bromo [G9], 2-chloro [GIO] and 4-chloro [G7] 
compounds were lower than those of more hydrophilic 4-
methoxy [G6], 4-dimethylamino [G5], 3-nitro [G1] and 2-nitro 
[Gll] ompounds. It was concluded that MDR-modulating 
activ y of the present series of compounds could not be 
determined by lipophilicity alone, but lipophilicity may be 
le.*arded as a favorable parameter within a homologous 
series. 
Discussion 
Eff cts of calcium chann l blockers with structure distinct 
from VP have been studied for anti-MDR activity. The DHP 
analogs, niludipine, nimodipine and nicardipine were found 
to be potent antagonists of MDR, i.e., its combination with 
3.5-10 ~tM nicardipine fuliy reversing vincristine resistance in 
P3881VCR and K5621VCR cells and partially reversing 
doxorubicin resistance in P388/ADR cells (23). It is suggested 
that P p seems to be a good accept30r, as judged by the 
inhibition of photolabeling of Pgp by [ H]azidopine by DHP 
analogs (5d, 5e). Additional y, the inhibition was significantly 
c rrelated wi h their reversing activity (5d, 5e). To find an 
agen  which lacks calcium-antagonistic activity, but still 
possesse  MDR reversal activity, several DHPS Were screened 
on their bility to reverse MDR. However, no specific 
structural features could be identified by chemosensitizing 
activity (5). As modified DHP calcium channel blockers, the 
role of the C-3 and C-5 substituents in DHP ring has received 
attention, because derivatives with 3,5-diacetyl groups have 
reduced calcium antagonistic activity. Compounds Gl, GIO 
and G11 have been reported to possess an approximately 
equiv lent oten y of calcium antagonistic activities, as 
assessed by their a il ty,t+0 relax established constractions 
induced by I mol/L Ca~ (15). Comparison of the calcium 
a tagonistic pot cy of these three compounds and NP shows 
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